Promising leukemia combo trial pulled before it began
NCT ID NCT07052994
First seen Mar 08, 2026 · Last updated Jun 20, 2026 · Updated 16 times
Summary
This study aimed to find a safe dose of revumenib when given with standard chemotherapy drugs for children and young adults with acute leukemia. It was designed for patients with certain genetic markers. However, the trial was withdrawn before any participants were enrolled, so no data was collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC ACUTE LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
revumenib (a targeted drug) combined with chemotherapy drugs (cytarabine, daunorubicin, gemtuzumab ozogamicin)
What this could lead to
If it had worked, this could have pointed toward a new treatment option for children with certain types of acute leukemia.
What could go wrong
This trial was withdrawn before enrolling any participants, so no results are available. The combination may have caused severe side effects or failed to control the disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.